Drawing for EMPRISE

USPTO serial 79229786

EMPRISE

Reviewed by CopyMark Law Group

Reg. 5663596Status 706Registered
Filing date
Status date
Registration date
Jan 29, 2019
Examiner
COLLOPY, DIANE PATRICIA
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with EMPRISE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Max Moskowitz

Max Moskowitz Ostrolenk Faber LLP845 THIRD AVENUE, 17th FloorNew York, NY 10022United States

Goods and services

ClassDescriptionStatusFirst use
042Medical and scientific research in the field of diabetes, cardiovascular diseases, chronic kidney disease and epidemiological studies; providing medical and scientific research information in the field of pharmaceuticals and clinical trialsACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 27, 2025NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
May 27, 202571AGREGISTERED-SEC.71 ACCEPTED
May 26, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 29, 2025ES71TEAS SECTION 71 RECEIVED
Jan 29, 2024REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Jun 14, 2019FINOFINAL DECISION TRANSACTION PROCESSED BY IB
May 24, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB
May 23, 2019FIMPFINAL DISPOSITION PROCESSED
Apr 29, 2019FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 29, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Nov 13, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 13, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 9, 2018GPNXNOTIFICATION PROCESSED BY IB
Oct 24, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 24, 2018OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 24, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 26, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Sep 25, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Sep 25, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 25, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 28, 2018RFNTREFUSAL PROCESSED BY IB
Apr 12, 2018RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 12, 2018RFRRREFUSAL PROCESSED BY MPU
Apr 10, 2018RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 10, 2018MAFRAPPLICATION FILING RECEIPT MAILED
Apr 9, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 6, 2018DOCKASSIGNED TO EXAMINER
Apr 6, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 5, 2018REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance